antioxidant properties of this plant has been well documented [11, 12] . The flowers of this plant are edible and are consumed as a popular traditional remedy for night blindness, bronchitis, nasal catarrh, headache and frontal sinus pain alleviation [13] . Recently, two proteins, namely SGF60 and SGF90 isolated from the flowers of this plant have been shown to inhibit ␣-glucosidase, and hence has been speculated as a potential drug against type 2 diabetes [14] . Even though Ayurvedic literatures [15] 
Materials and methods

Reagents and antibodies
Drug extraction
Fresh flowers of S. grandiflora were ground in phosphate buffered saline (PBS) in ice and the extract was filtered using cheese cloth and was further subjected to centrifugation at 2000 rpm for 10 min. at 4ЊC. The clear supernatant was subjected to protein precipitation using ammonium sulphate saturation and the three fractions (0-40% [SF1], 40-70% [SF2] and 70-100% [SF3]) obtained were centrifuged, dialysed, passed through
Sephadex G-25 column and lyophilized as described earlier [16] .
In vitro studies
The murine ascites tumour cell lines -DLA and Ehrlich ascites (EAC), the normal murine cell line -murine embryonic fibroblast (MEF), the human lung cancer cell lines -A549 and H1299, the human cervical cancer cell lines -HeLa and ME-180 and the human colon cancer cell lines -SW-480, SW-620 and HT-55 were used for the in vitro studies. The cytotoxicity was measured by MTT assay [17] . Inhibition of DNA synthesis and DNA damage was assessed by [ 3 H]thymidine incorporation assay and DNA fragmentation assay, respectively [18] . Annexin V-FITC staining was done according to manufacturer's protocol [17] . The cleavage of caspases 3, 8 and 9 induced was detected by Western blot and assayed spectrofluorimetrically as described earlier [19] . Cleavage of PARP, the inhibition of Akt phosphorylation and down-regulation of Bcl-2 and COX-2 expression were detected by Western blot [19] . Mitochondria-free cytosol was isolated as described earlier [17] and immunoblotted against anti-cytochrome C. NF-B down-regulation was studied by electrophoretic mobility shift assay (EMSA) [18] .
In vivo studies
Ascites tumour model [20] . [21] . Blood collected from the ocular vein was studied for the total and differential counts of white blood cell (WBC) and the haemoglobin content [22] . The activity of serum alkaline phosphatase (ALP) was determined by the method of King and Armstrong [23, 24] and the level of blood urea nitrogen (BUN) was evaluated according to standard protocol [25] . The activity of serum and liver glutamate oxaloacetic transaminase (GOT) and glutamate pyruvic transaminase (GPT) was determined by the Reitman and Frankel method [26] . (Fig. 2C) . We also observed a dose-dependent release of cytochrome C from the mitochondria to the cytoplasm, strongly indicating that the apoptosis induced by SF2 is through the mitochondrial pathway (Fig. 2D ).
Toxicological analysis Chronic toxicity
Acute toxicity
SF2 reduces Ascites as well as solid tumour development in Swiss albino mice
As the in vitro studies showed promising results, we conducted an in vivo study of SF2 using ascites and solid tumour models as described in the section 'Materials and methods'. In the ascites tumour model, the average lifespan of the positive control mice (group III) was 25 days and developed a visible tumour after 14 days, whereas the animals that were treated with SF2 24 hrs after tumour transplantation (group IV) did not develop any visible tumours for the first 25 days. These animals had an increase in
lifespan of 105% compared to the positive control. In the case of group V animals, which were treated with the drug 7 days after tumour transplantation, even though the growth of tumour was delayed, the increase in lifespan was 49% indicating that chemopreventive efficacy of SF2 is much higher than its anti-tumour effect (Fig. 3B) . There was no tumour development in the negative control groups (group I) which were kept under observation and monitored for 6 months.
In the solid tumour model, to our surprise, the group III animals, which received the drug 1 day after tumour transplantation, did not develop any tumour during the observation period. However, group IV animals that received the drug, 7 days after tumour transplantation, developed tumours initially, but further growth of tumour was arrested, again indicating the chemopreventive efficacy of the drug (Fig. 3C) . A substantial increase in the lifespan (54%) was also noted.
SF2 does not produce any toxicity in the blood, liver or kidney of Swiss albino mice
To rule out the possibility of any adverse side effects of SF2 we conducted a detailed toxicity study, both chronic and acute. In the chronic toxicity study, we evaluated the haematotoxicity, nephrotoxicity and hepatotoxicity due to the SF2 fraction by analysing the level of the total and differential WBC count (Fig. 4A) , serum ALP (Fig. 4B), level of BUN (Fig. 4C ) and GOT and GPT profiles in serum and hepatic tissues (Fig. 4D) 
SF2 induces cytotoxicity to human cancer cells and induces apoptosis in the colon cancer cell line, SW-480
The promising data obtained using the murine ascites cell lines both in the in vitro and in vivo conditions encouraged us to extend Fig. 1 SF2 induces (Fig. 5D) . Our results support the notion that SF2 treatment initiates signalling pathways leading to apoptosis. (Fig. 6C) . SF2 also down-regulated the expression of COX-2 which also provides survival advantages to cancer cells (Fig. 6D) . Phosphorylation of Akt, another survival signal that in many cases is regulated by NF-B [27, 28] , was also inhibited by SF2 (Fig. 6E) .
SF2 down-regulates the activation of anti-apoptotic factors, NF-B, Bcl-2, Akt and COX-2 induced by PMA
We also explored whether SF2 can down-regulate various survival signals which are the key regulators of apoptosis. We observed a dose-dependent inhibition of NF-B by SF2, in SW-480 cells
Fig. 2 SF2 induces activation of caspases, DNA fragmentation, PARP cleavage and cytochrome-C release in DLA cells. (A) Cells treated for 24 hrs with indicated concentrations of SF2 were lysed, centrifuged and the supernatant was used for assaying the caspases 8, 9 and 3 activities, respectively, using appropriate fluorogenic substrates. Cell lysates were blotted against specific antibodies for the respective caspases. (B) The cells were treated with indicated concentrations of SF2 for 24 hrs; DNA was extracted and subjected to electrophoresis. (C) Cells treated for 24 hrs with indicated concentrations of SF2, were lysed and blotted against anti-PARP antibody. (D) Cells were treated with SF2 for 24 hrs, and mitochondria-free cytosol was prepared and blotted against anticytochrome-C and ␤-actin antibodies. treated with PMA, a well-known inducer of NF-B (Fig. 6A). Antibodies against both p50 and p65 subunits of NF-B shifted the active NF-B complex producing super shifts whereas incubation with excess unlabelled oligonucleotide containing the NF-B binding site completely removed the active complex confirming the specificity of the bands (Fig. 6B). Since SF2 induced the release of cytochrome C from the mitochondria, the involvement of mitochondrial pathway is evident in SF2-induced apoptosis. Hence we investigated the role of SF2 in regulating Bcl-2, the mitochondrial membrane bound anti-apoptotic factor. We observed a strong and dose-dependent down-regulation of Bcl-2 by SF2
Taken together, the above noted novel mechanistic observations strongly attest the potential anticancer efficacy of SF2, in both in vitro and in vivo model systems.
Discussion
In this study we have documented findings pertinent to the prospect for therapeutic applications of S. grandiflora. An active fraction (SF2) derived from the flower of S. grandiflora contains a pharmacologically safe pro-apoptotic compound. Despite existing anecdotal information on anticancer properties associated with the fruit of this plant in the Indian system of medicine (Ayurveda), no information exemplifying anti-tumour efficacy of flowers of this plant exists in the literature. Our studies revealed that flowers of S. grandiflora are associated with more potent anticancer efficacy compared to the leaves and fruit (data not shown). We elucidated the mechanistic pathway through which an active fraction of the flower, SF2, induced apoptosis in murine, as well as in human cancer cell lines, and confirmed its anticancer effect in mice bearing ascites and solid tumours.
Although the mechanism by which SF2 achieves these effects remains unknown, several studies document that caspase activation and subsequent cleavage of functionally essential key enzymes perform a central role in the biological processing of apoptosis [29] . In concordance with the currently acceptable dogma for apoptosis, SF2 induced a dose-dependent activation of the caspases 3, 8 and 9 (both spectrofluorimetrically and by Western blot) and cleaved the full length PARP into the apoptotic fragments. Furthermore, a dose-dependent release of cytochrome C from the mitochondria to the cytoplasm strongly indicates that the apoptosis induced by SF2 is through the mitochondrial pathway. However, it remains to be tested whether SF2-mediated apoptosis also operates through caspase-independent apoptogenic proteins such as apoptosis inducing factor and endonuclease G [30, 31] .
As biological therapy for treatment of cancer, SF2 treatment given to mice 24 [39] . Extensive studies reported in literature indicate that the anti-apoptotic protein Bcl-2 inhibits the release of apoptogenic cytochrome C from mitochondria into the cytosol [40, 41] , suggesting that Bcl-2 may participate in stabilizing mitochondria [42] . Aberrant overexpression of Bcl-2 rescues precancerous cell clones from apoptotic elimination. Existing data suggest a potential role for Bcl-2 in altering NF-B activity [43, 44] . It has been suggested that signalling pathways that lead to NF-B down-regulation are mediated by one of the Bcl-2 homology domains that are conserved among members of the Bcl-2 gene family [45] . [46, 47] 
Several studies including ours have shown that antioxidants and vitamins significantly down-regulate anti-apoptotic factors contributing to anticancer effect
